Bioverativ and Bicycle Therapeutics will jointly work on blood disease therapies

| |
0
67

Bioverativ Inc., a global biotechnology company focused on the discovery, development and commercialization of innovative therapies for hemophilia and other rare blood disorders, and Bicycle Therapeutics Ltd., a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, today announced a research collaboration focused on the discovery, development and commercialization of innovative therapies for hemophilia and sickle cell disease.

The collaboration will seek to identify and develop Bicycles to treat rare blood disorders. Bicycles are a new therapeutic modality that combine attributes of antibodies, small molecules and peptides within one molecule, enabling high selectivity and affinity while simultaneously being able to penetrate and bind to the target(s) of interest within the body.

Bicycle Therapeutics will be responsible for leading initial discovery activities through lead optimization to candidate selection for two programs. Bioverativ will lead preclinical and clinical development, as well as subsequent marketing and commercialization.

“We are constantly exploring new ways to do innovative science to find new molecules that can advance the care of people living with rare blood disorders,” said Tim Harris, Ph.D., D.Sc., Executive Vice President of Research and Development at Bioverativ. “This collaboration offers a unique opportunity to identify an entirely new therapeutic modality that may lead to meaningful new treatments and outcomes for people living with hemophilia and sickle cell disease. We are delighted to be working with Bicycle to pursue our shared goal of creating progress for patients with great unmet treatment needs.”

“We believe our Bicycle platform has extremely broad therapeutic potential and we are excited to work with Bioverativ, a standout leader in the hematology field, to explore Bicycles in this important area of clinical need,” said Kevin Lee, Chief Executive Officer of Bicycle Therapeutics. “Combining Bioverativ’s deep expertise in hematology with our powerful platform offers great promise for the development of novel, targeted therapies for patients. This alliance provides the latest validation of our Bicycle platform and furthers our strategy to evaluate its potential in a wide range of new disease areas.”

SOURCE: bioverativ
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.
Isaltis Banner